U.S. FDA Grants RMAT Designation to GS-100 for NGLY1 Deficiency
Wednesday, April 15, 2026
Grace Science, LLC has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for GS-100, an investigational gene therapy for the treatment of NGLY1 deficiency.
GS-100 is an AAV9-based gene replacement therapy currently in clinical development for this ultra-rare genetic disorder, which has no approved treatment options.
The designation is supported by early clinical evidence from an ongoing open-label, single-arm, dose-finding Phase 1/2/3 trial evaluating the long-term safety, tolerability and effectiveness of the therapy. Patients treated with GS-100 for at least 52 weeks have shown improvements in motor function and cognitive abilities. These include better ability to sit, stand or walk with support, along with improved attention and interaction.
The RMAT designation highlights the potential of GS-100 based on preliminary clinical data and provides a more streamlined pathway for development and regulatory review. The programme is intended to accelerate the development of regenerative medicine therapies for serious or life-threatening conditions and may support faster approval if required criteria are met.
GS-100 remains an investigational therapy, and its safety and efficacy have not yet been fully established.
Source: businesswire.com
